Literature DB >> 9793665

Liver function after sevoflurane or isoflurane anaesthesia in neurosurgical patients.

T Nishiyama1, T Yokoyama, K Hanaoka.   

Abstract

PURPOSE: Although both sevoflurane and isoflurane are thought to be less hepatotoxic than halothane or enflurane, recent case reports have described liver injury after sevoflurane or isoflurane anaesthesia. There are no studies comparing liver function after sevoflurane or isoflurane anaesthesia. The purpose of this study was to compare serum liver enzyme concentrations in patients receiving either sevoflurane or isoflurane anaesthesia prospectively.
METHODS: Ninety patients scheduled for elective neurosurgery were studied. Serum concentrations of aspartame aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBil), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GTP), and lactate dehydrogenase (LDH) were measured before and, 1, 2, 3, 7, and 14 days after either sevoflurane (45 patients) or isoflurane (45 patients) anaesthesia.
RESULTS: AST, ALT and GTP increased peaking seven days after anaesthesia, especially in the isoflurane group. The numbers of patients with abnormal values in AST and ALT were not different in the isoflurane from that in the sevoflurane group. The increase in TBil peaked one day after anaesthesia in both groups.
CONCLUSION: Even in a small number of patients, isoflurane induced an elevation of serum levels of liver enzymes more frequently than did sevoflurane three to 14 days after anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793665     DOI: 10.1007/BF03012146

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  10 in total

1.  Inclusion of a nitric oxide congener in the insufflation gas repletes S-nitrosohemoglobin and stabilizes physiologic status during prolonged carbon dioxide pneumoperitoneum.

Authors:  Kazufumi Shimazutsu; Kenichiro Uemura; Kathryn M Auten; Matthew F Baldwin; Samuel W Belknap; Francisco La Banca; Maximilian C Jones; Deborah J McClaine; Rebecca J McClaine; W Steve Eubanks; Jonathan S Stamler; James D Reynolds
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

Review 2.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

3.  Changes in the level of serum liver enzymes after laparoscopic surgery.

Authors:  Min Tan; Feng-Feng Xu; Jun-Shen Peng; Dong-Ming Li; Liu-Hua Chen; Bao-Jun Lv; Zhen-Xian Zhao; Chen Huang; Chao-Xu Zheng
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  The effects of N-acetylcysteine on hepatic function during isoflurane anaesthesia for laparoscopic surgery patients.

Authors:  Serbülent Gökhan Beyaz; Birgul Yelken; Güngor Kanbak
Journal:  Indian J Anaesth       Date:  2011-11

Review 5.  The role of inhalational anesthetic drugs in patients with hepatic dysfunction: a review article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Hoorolnesa Ameli; Seyed Moayed Alavian
Journal:  Anesth Pain Med       Date:  2015-01-07

6.  Comparative effect of desflurane and sevoflurane on liver function tests of patients with impaired hepatic function undergoing cholecystectomy: A randomized clinical study.

Authors:  Rabie Soliman; Abdelbadee Yacoub; Mostafa Abdellatif
Journal:  Indian J Anaesth       Date:  2020-05-01

7.  Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome.

Authors:  Puyuan Wen; Lisha Wang; Hong Liu; Li Gong; Han Ji; Hongliang Wu; Wenzheng Chu
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

Review 8.  Anesthesia for patients with liver disease.

Authors:  Poupak Rahimzadeh; Saeid Safari; Seyed Hamid Reza Faiz; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

9.  Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.

Authors:  Oliver A Cornely; José M Cisneros; Julian Torre-Cisneros; María Jesús Rodríguez-Hernández; Luis Tallón-Aguilar; Esther Calbo; Juan P Horcajada; Christian Queckenberg; Ulrike Zettelmeyer; Dorothee Arenz; Clara M Rosso-Fernández; Silvia Jiménez-Jorge; Guy Turner; Susan Raber; Seamus O'Brien; Alison Luckey
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

10.  Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

Authors:  Carlos Chaccour; Gloria Abizanda; Ángel Irigoyen-Barrio; Aina Casellas; Azucena Aldaz; Fernando Martínez-Galán; Felix Hammann; Ana Gloria Gil
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.